Core Viewpoint - Company reported a significant decline in Q1 2025 revenue and net profit, attributed to high base effects and weak demand, prompting a need for strategic adjustments in product and channel management [1][2][3] Financial Performance - Q1 2025 revenue reached 1.79 billion yuan, down 32.3% year-on-year; net profit attributable to shareholders was 450 million yuan, down 37.4%; and net profit excluding non-recurring items was 410 million yuan, down 42.4% [1] - The main brand "汤臣倍健" generated 983 million yuan in revenue, a decrease of 36.37% year-on-year; "健力多" revenue was 201 million yuan, down 46.15%; and Life-Space domestic products brought in 77 million yuan, down 36.19% [1] - International business, represented by LSG, achieved revenue of 244 million yuan, up 5.94% year-on-year, indicating relative stability [1] - Offline channel revenue was 988 million yuan, down 42.62%; online channel revenue was 766 million yuan, down 15.78%, with offline sales significantly impacted by reduced foot traffic and high base effects [1] Cost Management - Q1 2025 gross margin was 68.66%, a decrease of 1.24 percentage points, primarily due to a higher proportion of low-margin products and increased fixed costs from declining revenue [2] - Sales expense ratio was 30.29%, down 0.91 percentage points, reflecting effective cost control measures [2] - Management expense ratio increased to 5.77%, up 1.02 percentage points, due to the decline in revenue [2] - Overall, the net profit margin for Q1 2025 was 26.04%, down 1.13 percentage points year-on-year [2] Strategic Initiatives - In Q2, the company plans to launch new products aimed at revitalizing offline channel sales, including new formats for vitamins and probiotics, and targeting essential consumer groups [3] - The company will conduct offline product launch events to enhance brand visibility and consumer engagement [3] - Profit forecasts for 2025-2027 have been revised downwards due to ongoing weak demand, with projected net profits of 791 million yuan, 921 million yuan, and 1.024 billion yuan, representing reductions of 13%, 17%, and 19% respectively [3] - The company maintains a "buy" rating, emphasizing its leadership position in the dietary supplement industry and the sector's growth potential [3]

证券研究报告 | 季报点评 gszqdatemark 2025 04 27 年 月 日 汤臣倍健（300146.SZ） 经营压力释放，期待逐季向好 事件：公司发布 2025 年一季报，25Q1 实现营收 17.9 亿元，同比-32.3%； 实现归母净利润 4.5 亿元，同比-37.4%；实现扣非净利润 4.1 亿元，同比 -42.4%。 高基数及春节错期仍有压力，线下渠道客流量压力更大。25Q1 公司收入 增长仍有承压，我们认为主要受上年同期基数为全年较高、今年春节错期、 消费力偏弱且行业维持较高强度竞争影响。分渠道来看，25Q1 公司线上/ 线下收入同比-15.8%/-42.6%，线下渠道上年同期基数较高，且预计仍受 保健品行业整体线下渠道人流量承压、线上为主要增量渠道影响。分品牌 来看，25Q1 汤臣倍健主品牌/健力多/Life-spacce 国内/LSG 境外收入分别 同比-36.4%/-46.2%/-36.2%/+5.9%，线下占比较高的主品牌、健力多、 Life-spacce 国内收入增长压力较明显，而 LSG 境外表现相对稳健。 毛利率因产品结构及规模效应承压，费用管控效果逐步显现。25Q1 毛利 ...